scFv(MSLN)-CD28-CD3zeta CAR-T Lentivirus

scFv(MSLN)-CD28-CD3ζ CAR-T Lentivirus is a gene-delivery reagent developed to generate T cells that recognize mesothelin (MSLN), a cell-surface glycoprotein overexpressed in several solid tumors. The encoded second-generation chimeric antigen receptor contains an extracellular anti-MSLN single-chain variable fragment (scFv), membrane-anchoring elements, the intracellular costimulatory domain of CD28, and the CD3ζ activation domain. The scFv directs antibody-like recognition of surface MSLN without requiring peptide presentation by the major histocompatibility complex. Following antigen engagement, CD3ζ initiates the primary activation signal, while CD28 provides costimulation that supports T-cell activation, proliferation, cytokine production, and effector function. Lentiviral delivery enables efficient gene transfer and stable CAR expression in transduced T cells, creating a practical and reproducible platform for studying MSLN-directed immune responses.

This product is intended for research on mesothelin-targeted cellular immunotherapy and the functional characterization of CD28-based CAR-T cells. It can be used to prepare experimental CAR-T cells for assessing receptor expression, MSLN-dependent activation, target-cell killing, cytokine release, proliferation, and changes in differentiation or exhaustion markers. Comparisons among MSLN-high, MSLN-low, and MSLN-negative target cells can help determine antigen-density requirements, selectivity, and possible on-target effects across different expression levels. The resulting cells are suitable for appropriately designed studies involving malignant mesothelioma, pancreatic cancer, ovarian cancer, esophagogastric cancer, and other MSLN-expressing solid-tumor models. This construct may also serve as a reference for comparing CD28 signaling with first-generation CD3ζ-only receptors or CARs containing alternative costimulatory domains such as 4-1BB. Additional applications include examining soluble or shed mesothelin, repeated antigen exposure, tumor-cell resistance, immune escape, and suppression within the tumor microenvironment. The lentiviral format helps streamline exploratory screening, mechanistic studies, and early-stage evaluation of combination strategies involving checkpoint inhibitors, targeted agents, cytokines, or other immune-modulating approaches.